Nisshinyaku <4516> is sharply rising. J&J announced that it has obtained manufacturing and marketing approval for the combination tablet "Yubanshi Combination Tablet," which contains the endothelin receptor antagonist macitentan 10mg and the phosphodiesterase 5 inhibitor tadalafil 40mg, for the treatment of pulmonary arterial hypertension. There is a positive movement towards expanding into the field of pulmonary hypertension, which is positioned as one of the areas of focus.